|
AstraZeneca two-in-one
drug succeeds in lung disease test
Send a link to a friend
[March 18, 2015]
LONDON (Reuters) - AstraZeneca said
on Wednesday its experimental lung drug PT003 for chronic lung disease
had proved successful in two final-stage Phase III trials, boosting
hopes for the company's respiratory pipeline.
|
|
 The drug, which AstraZeneca acquired after buying Pearl Therapeutics
two years ago, combines a long-acting beta-2 agonist (LABA) and a
long-acting muscarine antagonist (LAMA). AstraZeneca plans to file
PT003 for approval commencing in 2015.
Rival firms also have LAMA/LABA drugs that are more advanced than
PT003, but AstraZeneca's drug is administered with a pressurized
meter-dose inhaler instead of a dry-powder inhaler, which may suit
elderly patients in particular.
(Reporting by Ben Hirschler, editing by Louise Heavens)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
 |
